Knowledge Exchange by ISID

Maximum: 1 CME cr.,
1 AutoAttendance cr.
Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
Disclosure/Disclaimer Discl...

Activity Title: COVID-19 Alpha through Mu: Variant and Treatment Update

Release Date: October 12, 2021

Estimated Time to Complete Activity: 60 minutes

Statement of Need:

As COVID-19 variants continue to emerge and spread globally, ISID is pleased to provide an expert panel to discuss latest developments. This webinar will continue our review of the COVID-19 pandemic by examining how SARS-CoV-2 has mutated, the different variants - including delta and lambda - and the impact on fragile, or at risk communities. Special consideration is given to the paediatric population. We shall also discuss the impact of these variants on the efficacy of current vaccines and how to prevent the emergence of future variants.

Faculty:
Professor Shabir Madhi
Professor of Vaccinology, University of the Witwatersrand
Director: South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit (VIDA).
Co-Director African Leadership in Vaccinology Expertise (ALIVE)

Professor Sir Andrew Pollard
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FIDSA, FRCPCH, MA, FMedSci
Professot of Paediatric Inefection and Immunity

Technical Requirements

This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content a broadband connection is required. For CME/CE activities featuring audio you need a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.

Contact Information

If you have questions about this CME activity, please contact The International Society for Infectious Diseases at  info@isid.org.

For technical support issues, please contact Multilearning at support@multilearning.com

 

Upon completion of this module, participants should be able to:

  • Discuss how SARS-CoV-2 has mutated, the different variants - including delta and lambda
  • Discuss the impact on fragile, or at risk communities
  • Understand current thinking on the effect of the virus on the paediatric population
  • Discuss the impact of Covid variants on the efficacy of current vaccines and how to prevent the emergence of future variants.

Physicians, nurses, public health officials, researchers, and other health professionals

Disclosure Policy

In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID  resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose. 

ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here along with Committee members’ disclosure forms. 

Faculty Disclosures:

Professor Shabir Madhi
Affiliation/Financial Interest and Name of Commercial Company
Grants/Research Support: Bill and Melinda Gates Foundation, South Africa Medical Research Council, Novavax
Sponsored Speakers Bureau: Cipla, Novartis

Professor Andrew Pollard 
Affiliation/Financial Interest and Name of Commercial Company
Grants/Research Support: AstraZeneca: Worked in partnership to develop Oxford-AstraZeneca COVID-19 vaccine

Moderator Disclosures:
Prof. Neelika Malavige
Affiliation/Financial Interest and Name of Commercial Company
Receipt of honoraria or consultation fees: Sun Pharma (India)

Disclosure of Unlabeled Use

The International Society for Infectious Diseases  requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.

Copyright Information

Copyright © 2021 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

•  The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

•  Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.

Privacy Policy

The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/ and https://exchange.isid.org/isid/legal/terms-and-conditions.

ACCREDITED ACTIVITY
COVID-19 Alpha through Mu: Variant and Treatment Update

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies